ACMD public evidence request on cognition enhancers

The ACMD are inviting relevant stakeholders to provide submissions of written evidence to support its workstream on cognition enhancers (also known as ‘nootropics’, or study drugs).

The workstream aims to explore the prevalence, patterns and motivations for the use of cognition enhancers in the UK. The workstream will focus on, but not be limited to, the drugs modafinil, methylphenidate and dexamfetamine, and the harms to those who use these drugs outside of prescribed medical use.

If you would like to submit written evidence please

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.